Suzhou, China · Founded 2020 · In IPO Registration
Manufacturer of antibody-based biologics intended for autoimmune and allergic diseases. Longbio Pharma is based in Suzhou, China and was founded in 2020. Its last reported valuation was $278 million in May 2025. It has raised $76.7 million.
Last reported valuation
$277.8M
Oct 2026
Priced at
—
Total raised
$76.7M
Last round
—
Cap table — not yet on record
Longbio Pharma's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Longbio Pharma with a free account
·The complete investor list: 13 names
·Watch Longbio Pharma: the Monday email on marks, rounds and moves
